Corium International Inc  

(Public, NASDAQ:CORI)   Watch this stock  
Find more results for CORI
6.71
-0.25 (-3.59%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.71 - 7.00
52 week 6.10 - 8.49
Open 7.00
Vol / Avg. 5,565.00/28,501.00
Mkt cap 118.21M
P/E 10.17
Div/yield     -
EPS 0.66
Shares 17.62M
Beta     -
Inst. own 69%
May 13, 2014
Q2 2014 Corium International Inc Earnings Conference Call
May 13, 2014
Q2 2014 Corium International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 32.98% -27.60%
Operating margin -7.41% 2.39%
EBITD margin - 6.88%
Return on average assets 37.11% -34.17%
Return on average equity - -
Employees 243 -
CDP Score - -

Address

235 Constitution Drive
MENLO PARK, CA 94025
United States - Map
+1-650-2988012 (Phone)
+1-302-6555049 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. The Company�s marketed products are Clonidine Transdermal Delivery System (TDS), Fentanyl TDS and four Crest Advanced Seal Whitestrips products. It has developed two technology platforms, Corplex and MicroCor. It uses its Corplex technology to create advanced transdermal and transmucosal systems for small molecules that utilize less of the active ingredient. Its MicroCor technology is a biodegradable microstructure system under development that enables the painless delivery of biologics that otherwise must be delivered via injection. The advanced clinical-stage product in its pipeline is AG200-15, which is in Phase III development.

Officers and directors

Peter D. Staple President & CEO
Age: 62
Bio & Compensation  - Reuters
Robert Breuil Chief Financial Officer
Bio & Compensation  - Reuters
Tim Sweemer Chief Accounting Officer
Bio & Compensation  - Reuters
Christina Dickerson Vice President, Corporate Development
Bio & Compensation  - Reuters
Bobby Singh Ph.D. Vice President, Research & Development
Bio & Compensation  - Reuters